News >

IDO Plus PD-1 Inhibitor Combo Sparks Responses in Bladder and Cervical Cancers

Anita T. Shaffer @Shaffer1
Published: Sunday, Nov 12, 2017

Jason J. Luke, MD, FACP

Jason J. Luke, MD, FACP
The combination of nivolumab (Opdivo), a PD-1 inhibitor, and BMS-986205, a novel IDO inhibitor, generated promising response rates without increasing adverse effects in patients with advanced cervical or bladder cancers in an early-phase clinical trial that helps fuel growing interest in regimens that target the 2 immune checkpoint pathways.

“The IDO pathway is an important immunosuppressant pathway that is upregulated in the context of a productive interferon gamma–associated tumor microenvironment,” Luke said in the interview. “We initially thought of that as PD-L1 alone but we’re learning that most often when PD-L1 gets upregulated IDO gets upregulated as well and can act as a secondary immunologic or metabolic checkpoint to slow down T cells, even if you block PD-1.”

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x